Rystiggo

rozanolixizumab-noli

Approval

ApplicationBLA 761286
Approval dateJun 26, 2023
Approval year2023
SponsorUcb INC

FDA-approved use

To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Rystiggo: